Neglected disease; Trypanosoma brucei; Target repurposing; Phosphodiesterase inhibitors; TbrPDEB1; PDE5; sildenafil Tropical diseases such as human African trypanosomiasis (HAT), leishmaniasis, and Chagas' disease are often referred to as "neglected" diseases, as the low level of funding of drug discovery research is disproportionate to the total disease burden. For example, collectively these three diseases endanger over 73 million people globally 1 and create a burden of 4.5 million disability-adjusted lifeyears. 2 ,3 Yet, few compounds have advanced to clinical studies for these diseases. 4 The primary reason for this disparity is the high cost of drug discovery and unlikelihood that these research costs will be recouped by a research organization via drug sales to highly impoverished populations.
As a result, cost-effective methods for identification of lead matter and expediting compound optimization efforts are acutely needed. We apply the method of "target repurposing", wherein essential parasite enzymes are matched with proven, druggable human homologs. 4 By doing so, the research outputs of large and expensive programs of historical drug discovery projects can be used to initiate and drive optimization projects against parasitic targets.
Phosphodiesterases (PDEs) are a family of enzymes that maintain the balance of cAMP and cGMP in the cell, opposed to adenylate and guanylate cyclase, respectively. Humans possess eleven PDEs, several of which have been fruitfully pursued for drug discovery. The most well-known of these is PDE5, an enzyme that is inhibited by erectile dysfunction drugs such as Viagra™ (sildenafil, 1), Cialis™ (tadalafil, 2), and Levitra™ (vardenafil, 3), Figure 1 . Other PDEs are of demonstrated relevance to inflammatory conditions and CNS indications, such as schizophrenia. [5] [6] [7] Trypanosoma brucei, the causative agent of HAT, expresses five cAMP-specific PDEs, 8 two of which (TbrPDEB1 and TbrPDEB2) have together been shown by both RNAi 9,10 and small molecules 10, 11 to be essential for parasite proliferation. While initial benchmarking and early optimization experiments have uncovered a susceptibility of TbrPDEB1 and B2 to human PDE4 inhibitors, 11 the two trypanosomal enzymes are also 31% identical to PDE5 within their respective catalytic domains, and previous reports cited low potency of 1 and 2 against the trypanosomal enzymes; thus, we describe here early structureactivity relationships (SAR) of (1), and report such work for 2 in a subsequent article. We initially tested 1 for its inhibitory activity against the catalytic domain of TbrPDEB1, and observed low potency (51% at 100 µM). However, we deemed this chemotype worth further exploration given the extensive knowledge of SAR and structural biology around it. We performed activity scoping experiments by making strategic changes to the structure of 1, to explore the impact of variation of the N-methyl group and propyl chain on the pyrazolopyrimidinone core (Region A), and of the specific functionality on Region B. We were particularly interested in exploring the western portion of 1, as this region of the molecule was proposed to project into a parasite-specific pocket (the P-pocket). This pocket was first observed in the Leishmania major phosphodiesterase LmjPDEB1 13 and is predicted to also exist in TbrPDEB1, 11 but, importantly, is absent from all human PDEs. Compounds that explore Regions A and B were synthesized using the routes outlined in Schemes 1 and 2. The known aminopyrazole 4a 14 or 4b 15 was acylated with the appropriate benzoic acid and cyclized under basic conditions to give 5-10. Pyrazole N-arylation was achieved using copper catalysis 16 to prepare 11-13. Alkylation of 7 with bromoacetamide provided 14. Table 1 for the identity of Rgroups.
The preparation of Strategy B analogs of compound 1 is illustrated in Scheme 2. The appropriate aminopyrazole 15, 17 16, 18 or 17 19 is acylated with A using either CDI or PyBroP; these reaction conditions surprisingly resulted in the partial-to-complete hydrolysis of the primary amide (of 14 and 15) or ester (of 16). Thus, the resulting carboxylic acid 18 was converted to the primary amide 19 via treatment with thionyl chloride, followed by ammonia in isopropanol. Cyclization to the desired products was effected under basic conditions. Following synthesis, the analogs were tested in biochemical assays 11 at a single concentration. Notably, with one exception (7), none of the analogs that varied the pyrazole N1 substituent (H, Me, 3-pyridyl, or acetamide) nor the C3 position (H, Me, Pr, Ph) showed improved potency over 1. Compound showed lack of solubility, which precluded testing.
The removal of the N-methylpiperazinyl sulfonamide head group resulted in compounds with significant loss in solubility, and as such biochemical screening data was not possible with some analogs (Table 1, entries 8, 12-14) .
A broad exploration of heterocyclic substitutions in Region B was undertaken by application of parallel synthesis (Scheme 3). This was achieved by condensing the commercially available pyrazole amino amide 23 with various monocyclic heteroaromatic carboxylic acids that were available in pre-weighed quantities from a commercial vendor (ASDI, Inc). Following this amidation reaction, cyclization was achieved by treatment with sodium ethoxide in ethanol. Table 2 for the identity of R-groups.
A series of 2-alkoxy-3-pyridyl variations were prepared as shown in Scheme 4. The acylated aminopyrazole 25 was cyclized under basic conditions, using an appropriate alcoholic solvent, which yielded the 2-alkoxypyridyl derivatives 26. Table 2 summarizes the biochemical results for analogs prepared using this parallel methodology that display >25% inhibition at 100 µM (characterization and biochemical data for all compounds are listed in the Supporting Information). In brief, heterocycles show improved potency at TbrPDEB1, specifically, 2-methoxy-3-pyridyl and 3-methyl-2-pyridyl show the best potency (entries 1-2); larger 2-alkoxy groups (entries 3 and 4) lead to reduced activity. Unfortunately, dose-response experiments with 26c were precluded by poor solubility at higher concentrations. Tables 1 and 2 are modest, it is clear that 7, 26c and 24a represent qualitative potency improvement over 1. Nonetheless, the current exploration of the various regions of the sildenafil template is not suggestive of promising structure-activity relationship trends.
In conclusion, with the broad interest in repurposing PDE inhibitors for neglected diseases 11, 20, 21 and the extensive precedent in medicinal chemistry for human PDE5 inhibitors, we note our finding that these initial sildenafil analogs do not represent as strong starting points for further optimization for TbrPDEB inhibition as the PDE4 chemotypes previously reported. 11 This information may be deemed important for re-prioritizing the focus of these efforts.
